MCID: CRV002
MIFTS: 47

Cervix Uteri Carcinoma in Situ

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

MalaCards integrated aliases for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ 12 15
Carcinoma in Situ of Uterine Cervix 12 72
Cervical Intraepithelial Neoplasia 44 72
Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia 12
Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 72
Squamous Intraepithelial Neoplasia, Grade Iii 12
Cin Iii - Carcinoma in Situ of Cervix 12
Severe Dysplasia of the Cervix Uteri 12
Cin Iii - Severe Dyskaryosis 12
Carcinoma in Situ of Cervix 12
Carcinoma of Cervix Stage 0 12
Severe Dysplasia of Cervix 12
Cervix Ca in Situ 12
Cin Iii 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8991
ICD9CM 35 233.1
MeSH 44 D018290
NCIt 50 C4000
ICD10 33 D06 D06.9
UMLS 72 C0206708 C0851140 C2987516

Summaries for Cervix Uteri Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the uterine cervix.

MalaCards based summary : Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to cervicitis and chronic cervicitis. An important gene associated with Cervix Uteri Carcinoma in Situ is SERPIND1 (Serpin Family D Member 1), and among its related pathways/superpathways are Oncogene Induced Senescence and TP53 Network. The drugs Aluminum hydroxide and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and t cells, and related phenotype is mortality/aging.

Related Diseases for Cervix Uteri Carcinoma in Situ

Diseases in the Rare Cancer of Cervix Uteri family:

Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 cervicitis 32.0 SERPIND1 CDKN2A
2 chronic cervicitis 31.6 SERPIND1 GP6
3 cervical intraepithelial neoplasia 31.1 TERC KRT17 CDKN2A
4 in situ carcinoma 31.0 TP53 SERPIND1 KRT17 CDKN2A
5 cervix carcinoma 31.0 TP53 CDKN2A
6 suppressor of tumorigenicity 3 30.8 TP53 CDKN2A
7 balanoposthitis 30.8 GP6 CDKN2A
8 squamous cell papilloma 30.7 TP53 CDKN2A
9 keratinizing squamous cell carcinoma 30.7 TP53 CDKN2A
10 cervical carcinosarcoma 30.6 TP53 GP6
11 endocervical adenocarcinoma 30.6 TP53 CDKN2A
12 vulva cancer 30.5 TP53 CDKN2A
13 oropharynx cancer 30.5 TP53 CDKN2A
14 anogenital venereal wart 30.3 TP53 GP6 CDKN2A
15 cervix disease 29.2 TP53 SERPIND1 INSM1 GP6 CDKN2A
16 chlamydia 10.7
17 immune deficiency disease 10.6
18 vaginal discharge 10.5
19 inverted follicular keratosis 10.5 KRT17 GP6
20 bacterial vaginosis 10.5
21 bladder squamous cell carcinoma 10.5 TP53 CDKN2A
22 spitz nevus 10.5 TP53 CDKN2A
23 bladder carcinoma in situ 10.5 TP53 CDKN2A
24 scrotal carcinoma 10.5 TP53 CDKN2A
25 bartholin's gland disease 10.5 TP53 CDKN2A
26 nasal cavity adenocarcinoma 10.5 TP53 CDKN2A
27 vulvar disease 10.5 TP53 CDKN2A
28 thyroid lymphoma 10.5 TP53 CDKN2A
29 anal squamous cell carcinoma 10.5 TP53 CDKN2A
30 cervical cancer 10.5
31 gastric adenosquamous carcinoma 10.5 TP53 CDKN2A
32 glycogen-rich clear cell breast carcinoma 10.5 TP53 CDKN2A
33 retinoblastoma 10.5
34 familial retinoblastoma 10.5
35 megaesophagus 10.5 TP53 CDKN2A
36 oral leukoplakia 10.4 TP53 CDKN2A
37 meningeal melanomatosis 10.4 TP53 CDKN2A
38 dedifferentiated liposarcoma 10.4 TP53 CDKN2A
39 herpes simplex 10.4
40 cervix small cell carcinoma 10.4 TP53 CDKN2A
41 verrucous carcinoma 10.4 TP53 CDKN2A
42 early invasive cervical adenocarcinoma 10.4 INSM1 CDKN2A
43 necrotizing sialometaplasia 10.4 TP53 CDKN2A
44 fallopian tube endometrioid adenocarcinoma 10.4 INSM1 CDKN2A
45 tongue disease 10.4 TP53 CDKN2A
46 optic nerve neoplasm 10.4 TP53 CDKN2A
47 tonsil cancer 10.4 TP53 CDKN2A
48 juvenile pilocytic astrocytoma 10.4 TP53 CDKN2A
49 eccrine sweat gland neoplasm 10.4 TP53 KRT17
50 vaginal cancer 10.4

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):


Myofibroma

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:



Diseases related to Cervix Uteri Carcinoma in Situ

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

MGI Mouse Phenotypes related to Cervix Uteri Carcinoma in Situ:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.28 CDKN2A CINP COL27A1 GP6 INSM1 KLHL40

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
6 Monophosphoryl lipid A Phase 4
7 Lipid Regulating Agents Phase 4
8 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
9 Hypolipidemic Agents Phase 4
10 Anticholesteremic Agents Phase 4
11 Central Nervous System Depressants Phase 4
12 Anesthetics, Local Phase 4
13 Epinephryl borate Phase 4
14 Neurotransmitter Agents Phase 4
15 Sympathomimetics Phase 4
16 Adrenergic Agonists Phase 4
17 Respiratory System Agents Phase 4
18 Adrenergic alpha-Agonists Phase 4
19 Adrenergic beta-Agonists Phase 4
20 Mydriatics Phase 4
21 Adrenergic Agents Phase 4
22 Anti-Asthmatic Agents Phase 4
23 Vasoconstrictor Agents Phase 4
24 Autonomic Agents Phase 4
25 Bronchodilator Agents Phase 4
26
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
27
Bevacizumab Approved, Investigational Phase 3 216974-75-3
28
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
29
Pancrelipase Approved, Investigational Phase 3 53608-75-6
30
Eugenol Approved Phase 3 97-53-0 3314
31
leucovorin Approved Phase 3 58-05-9 143 6006
32
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
33
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
34
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
35
Aluminum sulfate Approved Phase 3 10043-01-3
36
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
38
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
39
Fenretinide Investigational Phase 3 65646-68-6
40
3,3'-diindolylmethane Investigational Phase 3 1968-05-4
41 Dermatologic Agents Phase 3
42 Retinamide Phase 3
43 Antibodies Phase 3
44 Immunoglobulins Phase 3
45 Antiviral Agents Phase 3
46 Keratolytic Agents Phase 3
47 Sodium Channel Blockers Phase 3
48 Diuretics, Potassium Sparing Phase 3
49 Anti-Arrhythmia Agents Phase 3
50 Angiogenesis Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 300)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
3 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
4 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
5 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
6 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
7 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
8 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
9 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
10 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
11 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
12 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
13 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Enrolling by invitation NCT02149030 Phase 4
14 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
15 A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 Completed NCT00003075 Phase 3 Fenretinide
16 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
17 Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693 Completed NCT00929526 Phase 3
18 Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study Completed NCT03355820 Phase 3
19 Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN) Completed NCT00212381 Phase 3 di indolylmethane (DIM)
20 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
21 An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1] Completed NCT00462813 Phase 3 oral microencapsulated diindolylmethane
22 Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial Completed NCT01505920 Phase 3
23 Single Visit Cervical Cancer Prevention Program Completed NCT00237562 Phase 3
24 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
25 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
26 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3 Fluorouracil
27 Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins Completed NCT01929993 Phase 3
28 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
29 Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Completed NCT02330471 Phase 3
30 A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ. Completed NCT00995020 Phase 3
31 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
32 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
33 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
34 Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens Completed NCT00973362 Phase 3
35 A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety Immunogenicity and Efficacy on the Incidence of HPV 16/18-Related CIN2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18,) L1 Virus-Like Particle (VLP) Vaccine (V501, Gardasil) in 16- to 23-Year Old Women - The F.U.T.U.R.E. II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) Completed NCT00092534 Phase 3
36 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
37 A Phase III, Randomized, Two-armed, Double-blind (Patient and Assessors), Parallel Active Controlled Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (Produced by AryoGen Pharmed) Plus FOLFIRI-3 Compared With Bevacizumab (Avastin®) Plus FOLFIRI-3 in Patients With Metastatic Colorectal Cancer (mCRC) Completed NCT03288987 Phase 3 Bevacizumab + FOLFIRI-3
38 Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women? Completed NCT01014026 Phase 3
39 A Randomized Phase III Trial of Oral Isotretinoin Versus Observation for Low-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Completed NCT00001073 Phase 3 Isotretinoin
40 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
41 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients. Completed NCT00677677 Phase 3
42 Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo Completed NCT02346227 Phase 3 AV2;Placebo
43 Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL Recruiting NCT03721978 Phase 3
44 A Phase III, Randomized, Two Armed, Parallel, Double-blind, Active-controlled, Equivalency Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, the Reference Drug, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients Recruiting NCT03391934 Phase 3 Cetuximab + FOLFIRI
45 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Recruiting NCT03998254 Phase 3 V503;Gardasil
46 The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Recruiting NCT03366493 Phase 3
47 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Recruiting NCT02669459 Phase 3 Imiquimod
48 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Active, not recruiting NCT01735006 Phase 3
49 A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix Active, not recruiting NCT03185013 Phase 3
50 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Genetic Tests for Cervix Uteri Carcinoma in Situ

Anatomical Context for Cervix Uteri Carcinoma in Situ

MalaCards organs/tissues related to Cervix Uteri Carcinoma in Situ:

41
Cervix, Testes, T Cells, Endothelial, Breast, Lymph Node, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Uteri Carcinoma in Situ:

19
Uterine Cervix

Publications for Cervix Uteri Carcinoma in Situ

Articles related to Cervix Uteri Carcinoma in Situ:

(show top 50) (show all 7447)
# Title Authors PMID Year
1
Effectiveness of cold coagulation in treating high-grade cervical intraepithelial neoplasia: the human papillomavirus evidence of cure. 38
31094247 2019
2
Erratum to "Proportion of cervical excision for cervical intraepithelial neoplasia as a predictor of pregnancy outcomes"[Int J Gynecol Obstet 128(2015) 141-147]. 38
31378937 2019
3
The efficacy of modified Swede Colposcopic Index in prediction of high-grade lesion and cancer of cervix. 38
31328460 2019
4
Nomogram-based prediction of cervical dysplasia persistence/recurrence. 38
30489353 2019
5
Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3. 38
31101617 2019
6
Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Systematic Review. 38
31403602 2019
7
Role of Close Endocervical Margin in Treatment Failure After Cervical Excision for Cervical Intraepithelial Neoplasia: A Retrospective Study. 38
30779593 2019
8
Prevalence and Determinants of High-risk HPV Infection among 11549 Women from an Opportunistic Screening in Hubei Province. 38
31347000 2019
9
Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology. 38
31160073 2019
10
Development of Algorithms for Automated Detection of Cervical Pre-Cancers With a Low-Cost, Point-of-Care, Pocket Colposcope. 38
30575526 2019
11
16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. 38
31409912 2019
12
The use of molecular markers for cervical screening of women living with hiv in South Africa. 38
31385866 2019
13
Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. 38
31182225 2019
14
High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil. 38
31189569 2019
15
Clinical Performance of Human Papillomavirus Testing and Visual Inspection With Acetic Acid in Primary, Combination, and Sequential Cervical Cancer Screening in China. 38
31295223 2019
16
Comparative efficacy and complication rates after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group. 38
31377697 2019
17
Cervical intraepithelial neoplasia grade 3 in a patient following Gardasil vaccination. 38
31401577 2019
18
Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay. 38
31002831 2019
19
Condom use to enhance regression of cervical intraepithelial neoplasia: study protocol for a randomized controlled trial. 38
31375148 2019
20
Dietary Inflammatory Index and Its Relationship with Cervical Carcinogenesis Risk in Korean Women: A Case-Control Study. 38
31382563 2019
21
Lower Genital Tract Dysplasia in Female Solid Organ Transplant Recipients. 38
31306332 2019
22
Peripheral blood circulating microRNA-4636/-143 for the prognosis of cervical cancer. 38
31407404 2019
23
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. 38
31255301 2019
24
Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol. 38
31320349 2019
25
Effects of exposure to polycyclic aromatic hydrocarbons combined with high-risk human papillomavirus infection on cervical intraepithelial neoplasia: A population study in Shanxi Province, China. 38
31290154 2019
26
Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3. 38
31272603 2019
27
Cytological Immunostaining of HMGA2, LRP1B, and TP63 as Potential Biomarkers for Triaging Human Papillomavirus-Positive Women. 38
31102921 2019
28
A systematic review and meta-analysis of thermal coagulation compared with cryotherapy to treat precancerous cervical lesions in low- and middle-income countries. 38
31273785 2019
29
High-risk Human Papillomavirus Testing in Young Japanese Women with Atypical Squamous Cells of Undetermined Significance. 38
31359920 2019
30
A Comparison of Cytomorphological Features of ASC-H Cells Based on Histopathological Results Obtained from a Colposcopic Target Biopsy Immediately after Pap smear Sampling. 38
31350977 2019
31
Role of FAM19A4/miR124-2 methylation analysis in predicting regression or non-regression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study. 38
31289088 2019
32
Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up study. 38
31375270 2019
33
Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. 38
31015201 2019
34
The diagnostic accuracy of colposcopy - A review of research methodology and impact on the outcomes of quality assurance. 38
31302386 2019
35
Development and evaluation of a cervical cancer screening system in Cambodia: A collaborative project of the Cambodian Society of Gynecology and Obstetrics and Japan Society of Obstetrics and Gynecology. 38
30977232 2019
36
Human papillomavirus genotype-specific risk in cervical carcinogenesis. 38
31074234 2019
37
Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. 38
31081870 2019
38
Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2. 38
31059006 2019
39
Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease. 38
30650180 2019
40
Diagnostic excision of the cervix in women over 40 years with human papilloma virus persistency and normal cytology. 38
31404426 2019
41
Detection of Oncoprotein by a Novel Immunochromatoghaphic Test Depending on Age and Parity of the Patients Attending at Mymensingh Medical College Hospital, Bangladesh. 38
31391418 2019
42
Long Term Effectiveness of Photodynamic Therapy for CIN Treatment. 38
31336848 2019
43
A direct comparison of four high-risk human papillomavirus tests versus the cobas test: Detecting CIN2+ in low-resource settings. 38
30854653 2019
44
Profile of the BD HPV OnclarityTM assay. 38
31155977 2019
45
Can we predict histological outcome of distinctive cohorts of patients with glandular cell abnormalities on ThinPrep Papanicolaou testing based on human papillomavirus status, age, and associated squamous abnormalities? 38
31359607 2019
46
Transforming human papillomavirus infection and the esophageal transformation zone: prime time for total excision/ablative therapy? 38
31304554 2019
47
Comparison of the AV Magnivisualizer device with colposcopy to detect cervical intraepithelial neoplasia using the Swede scoring system. 38
31353466 2019
48
Role of Chlamydia trachomatis serology in conservative management of cervical intraepithelial neoplasia grade 2. 38
31272132 2019
49
Prevalence of Cervical Intraepithelial Neoplasia in four Upazila of Dhaka Division. 38
31391440 2019
50
Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia. 38
31344234 2019

Variations for Cervix Uteri Carcinoma in Situ

Expression for Cervix Uteri Carcinoma in Situ

Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.

Pathways for Cervix Uteri Carcinoma in Situ

Pathways related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.66 TP53 CDKN2A
2
Show member pathways
10.3 TP53 CDKN2A
3 9.97 TP53 CDKN2A

GO Terms for Cervix Uteri Carcinoma in Situ

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.46 TP53 INSM1 CINP CDKN2A
2 positive regulation of cell cycle arrest GO:0071158 8.96 TP53 INSM1
3 replicative senescence GO:0090399 8.62 TP53 CDKN2A

Molecular functions related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.62 TP53 CDKN2A

Sources for Cervix Uteri Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....